definiens: shall mean any of the following indications for which the FDA grants Marketing Approval for aLixivaptan Product:(A ) euvolemic hyponatremia ( ), or(B ) euvolemic hyponatremia and hypervolemic hyponatremia, regardless of whether therapy is initiated insideor outside of a hospital ( ) ; where, means hyponatremia associated with the Syndrome of Inappropriate Anti - DiureticHormone secretion ( SIADH ), and means hyponatremia associated with Congestive Heart Failure ( CHF ), andApproval B shall be deemed received whether or not other forms of hypervolemic hyponatremia ( including hypervolemic hyponatremiaassociated with liver cirrhosis or hypervolemic hyponatremia in patients with acutely decompensated heart failure ) are contraindicated or thesubject of a warning in the label